DekaBank Deutsche Girozentrale Purchases New Stake in PetIQ, Inc. (NASDAQ:PETQ)

DekaBank Deutsche Girozentrale purchased a new stake in shares of PetIQ, Inc. (NASDAQ:PETQ) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,517 shares of the company’s stock, valued at approximately $50,000.

Other large investors have also recently bought and sold shares of the company. Natixis Advisors L.P. acquired a new position in PetIQ in the 1st quarter worth about $250,000. MetLife Investment Management LLC increased its position in PetIQ by 60.7% in the 1st quarter. MetLife Investment Management LLC now owns 15,255 shares of the company’s stock worth $372,000 after purchasing an additional 5,762 shares during the last quarter. BlackRock Inc. increased its position in PetIQ by 1.2% in the 1st quarter. BlackRock Inc. now owns 2,510,747 shares of the company’s stock worth $61,262,000 after purchasing an additional 29,457 shares during the last quarter. Dimensional Fund Advisors LP increased its position in PetIQ by 17.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 631,142 shares of the company’s stock worth $15,399,000 after purchasing an additional 94,759 shares during the last quarter. Finally, Sei Investments Co. increased its position in PetIQ by 18.7% in the 1st quarter. Sei Investments Co. now owns 235,346 shares of the company’s stock worth $5,732,000 after purchasing an additional 37,153 shares during the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

PetIQ Stock Performance

Shares of NASDAQ PETQ opened at $15.93 on Thursday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.43 and a current ratio of 2.27. The firm has a market cap of $468.82 million, a price-to-earnings ratio of 265.54 and a beta of 1.64. The business’s 50-day simple moving average is $17.52 and its 200-day simple moving average is $18.44. PetIQ, Inc. has a 52 week low of $10.98 and a 52 week high of $22.98.

PetIQ (NASDAQ:PETQ) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.22. The business had revenue of $219.93 million for the quarter, compared to analyst estimates of $189.70 million. PetIQ had a return on equity of 11.72% and a net margin of 0.19%. As a group, equities research analysts expect that PetIQ, Inc. will post 0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group upped their target price on PetIQ from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, PetIQ has a consensus rating of “Buy” and a consensus price target of $29.00.

About PetIQ

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.